Johnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis
Johnson & Johnson presented data from the Phase 3 ICONIC‑LEAD trial showing that, after 112 weeks of treatment, 72% of patients achieved at least a 90% improvement in PASI scores and about 70% reached clear or almost clear skin. The study enrolled 684 participants, including 66 adolescents, and safety remained consistent with the established profile. The company said the long‑term results support ICOTYDE as a first‑line oral therapy for moderate‑to‑severe plaque psoriasis.
Why it matters
The company’s press release notes that the sustained efficacy and safety could expand ICOTYDE’s market share in psoriasis, where it is already approved in the U.S., Europe, Japan and China. Investors may see revenue growth from increased adoption of the drug as a first‑line option.
Key facts
- 1The ICONIC‑LEAD trial enrolled 684 participants, of whom 456 received ICOTYDE and 228 received placebo. prnewswire.com
- 2The study included 66 adolescent patients. prnewswire.com
- 3At Week 112, at least 72% of ICOTYDE‑treated patients achieved PASI 90 (≥90% improvement). prnewswire.com
- 4From Week 64 through Week 112, about 70% of patients achieved clear or almost clear skin (IGA 0/1). prnewswire.com
- 5Complete skin clearance (PASI 100) was observed in 44% of patients, and 46% achieved IGA 0. prnewswire.com
- 6Clinically meaningful itch improvement was sustained in 78% of patients. prnewswire.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.